/biz/ - Business & Finance

>>19601410
>Sure AMRN did have stuff going for it
that's the opposite of what I was saying. Amarin DID NOT have stuff going in its favor, it had an FDA label expansion that the CEO tried to make a big deal out of, and a lawsuit that threatened to take that drug's exclusivity from them, which they subsequently lost.

They didn't reject big pharma, big pharma had more profitable ways to play heart disease. AMRN's model was low-price, which is the opposite of what heath benefit managers want. What the system wants is high cost drugs that can get high reimbursement or something like that.

If AMRN wins the appeal, it can squeeze up, but it's still not a gamble I am willing to take.